期刊文献+

西罗莫司结构修饰的研究进展 被引量:3

Structural modifications of sirolimus:research advances
下载PDF
导出
摘要 自西罗莫司作为免疫抑制剂应用于临床以来,便受到了人们的广泛关注。随着研究的深入,其生物利用度低、疏水性差以及结构不稳定等缺点的存在,使得该抗生素的临床应用受到了一定的限制,因此开发新型西罗莫司衍生物具有重要的研究和应用价值。近年人们对西罗莫司进行了大量的结构修饰研究,并从中获得了一系列有价值的衍生物。本文对西罗莫司结构修饰的最新研究进展作了一个简要的综述,并重点对几个结构修饰成功的西罗莫司衍生物作了较为详细的介绍。 Sirolimus was paid extensive attention since it was applied as immunosuppressant in clinic. Along with further study, the drawbacks of sirolimus such as the low bioavailability, low hydrophobic property and the instability of its structure restrict the clinic applications, therefore, it is necessary to explore new sirolimus derivatives. In the recent years, lots of study on the structural modifications of sirolimus have been made and obtained a series of valuable derivatives. This paper summarizes the structural modificatory advance of sirolimus and mainly introduces several successful sirolimus derivatives.
作者 柴宝红 陆群
出处 《国际药学研究杂志》 CAS 2008年第4期247-250,255,共5页 Journal of International Pharmaceutical Research
关键词 西罗莫司 衍生物 结构修饰 抗生素 sirolimus derivatives modification antibiotics
  • 相关文献

参考文献20

  • 1[1]Banaszynski LA,Liu CW,Wandless TJ,et al.Characterization of the FKBP-rapamycin-FRB ternary complex[J].J Am Chem Soc,2005,127(13):4715-4721.
  • 2[2]Vignot S,Faivre S,Aguirre D,et al.mTOR-targeted therapy of cancer with rapamycin derivatives[J].Ann Oncol,2005,16(4):525-537.
  • 3[3]Tsang CK,Qi H,Liu LF,et al.Targeting mammalian target of rapamycin (mTOR) for health and disease[J].Drug Discov Today,2007,12(3/4):112-124.
  • 4[4]Geoerger B,Kerr K,Tang CB,et al.Antitumor activity of the rapamycin analog CCl-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy[J].Cancer Res,2001,61(4):1527-1532.
  • 5[5]Grube E,Hauptmann KE,Buellesfeld L,et al.Six-month results of a randomized study to evaluate safety and efficacy of biolimus A9 eluting stent with a biodegradable polymer coating[J].EuroIntervention,2005,1(1):53-57.
  • 6[6]Wagner R,Mollison KW,Liu L,et al.Rapamycin analogs with reduced systemic exposure[J].Bioorg Med Chem Lett,2005,15(23):5340-5343.
  • 7[7]Von Burg GF.42-oxorapamycin[P].United States Patent:US-5023263,1991-06-11.
  • 8[8]Mark A,Roman S,Daniel T,et al.Rapamycin carbohydrate derivatives[P].World (PTC)Patent:WO-2004-101583,2004-11-25.
  • 9张亚,王明伟.新型免疫抑制剂构效关系的研究进展[J].中国新药杂志,2005,14(9):1109-1113. 被引量:6
  • 10[10]Holt DA,Keenan TP,Clackson TP,et al.Materials and method for treating or preventing pathogenic fungal infection[P].United States Patent:US-6693189,2004-02-17.

二级参考文献18

  • 1Suzuki S, Enosawa S, Kakefuda T, et al. A novel immunosuppressant, FTY720, with a unique mechanism of action, induces long-term graft acceptance in rat and dog allotransplantation[ J]. Transplant, 1996,61(2) : 200 - 205.
  • 2Fujita T,Hirose R, Yoneta M, et al. Potent Immunosuppressants, 2-Alkyl-2-aminopropane-1,3-diols [ J ]. J Med Chem , 1996,39 (22) :4451 - 4459.
  • 3Adachi K, Kohara T, Nakao N, et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1, 3-propanediols: Discovery of a novel immunosuppressant, FTY720 [ J].Bioorg Med Chem Lett, 1995,5(8) : 853 - 856.
  • 4Kiuchi M, Adachi K, Kohara T, et al. Synthesis and immunosuppressive activity of 2-substituted-2-aminopropane- 1,3-diols and 2-aminoethanols [ J ]. J Med Chem, 2000,43 ( 15 ) : 2946 - 2961.
  • 5Nadler SG, Dischino DD, Malacko AR, et al. Identification of a binding site on HscT0 for the immunosuppressant 15-deoxyspergualin[ J]. Biophys Biochem Res Commun, 1998,253 ( 1 ) : 176 - 180.
  • 6Lebreton L, Annat J, Derrepas P, et al. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 1.Structural modifications of the hydroxyglycine moiety [ J ]. J Med Chem, 1999,42(2) : 277 - 290.
  • 7Lebreton L, Jost E, Carboni B, et al. Structure-immunosuppressive activity relationships of new analogues of 15-deoxyspergualin. 2.Structural modifications of the spermidine moiety [ J]. J Med Chem,1999,42(23) :4749 - 4763.
  • 8Richter A, Davies DE, Alexander P. Growth inhibitory effects of FK506 and cyclosporin A independent of inhibition of calcineurin[ J].Biochem Pharmacol, 1995,49(3) : 367 - 373.
  • 9Ho S, Clipstone N, Tirtmaermann L, et al. The mechanism of action of cyclosporin A and FK506[J]. Clin Immunol Immunopathol, 1996,80(3) : S40- S45.
  • 10Kawai M, Lane BC, Hsieh GC, et al. Structure-actlvity profiles of macrolactam immunosuppressant FK-506 analogues [ J]. FEBS Lett,1993,316(2) : 107 - 113.

共引文献5

同被引文献61

  • 1吴晓慧,吴国荣,张卫明,顾龚平,沈奇.丹皮酚及其磺化物体外抗氧化作用[J].南京师大学报(自然科学版),2005,28(3):83-85. 被引量:25
  • 2姜国辉,王世真,江骥,李军,童强.氘代川芎嗪与川芎嗪药理作用比较(一)抗血栓及抗血小板作用[J].中国药理学通报,1996,12(2):133-137. 被引量:23
  • 3秦海娜,修志龙,张代佳,包永明,李晓晖,韩国柱.PEGylation of Hirudin and Analysis of Its Antithrombin Activity in vitro[J].Chinese Journal of Chemical Engineering,2007,15(4):586-590. 被引量:14
  • 4Sang S, Lambert JD, Yang CS. Bioavailability and stability issues in understanding the cancer preventive effects of tea polyphenols [J]. J Sci Food Agric, 2006, 86(14): 2256-2265.
  • 5Lam WH, Kazi A, Kuhn D J, et al. A potential prodrug fdr a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of ( - )-epigallocatechin gallate [ ( - )-EGCG][ J]. Bioorga & Med Chem, 2004, 12(21): 5587-5593.
  • 6钱名,杨保津,顾文华,等.丹参有效成分的研究I.丹参酮ⅡA磺酸钠和次甲丹参醌的化学结构[J].化学学报,1978,36(3):199-206.
  • 7Saulnier MG, Senter PD, Kadow JF, et al. Podophyllotoxin derivatives[ P]. UK: GB2207674 A. 1989-024)8.
  • 8Ramaiah S, Soundar D. Syntheses of N-vanillylnonanamide glycosides using amyloglucosidase from sweet almondl [ J ]. Biotechnol Lett, 2007,29 : 1537-1548.
  • 9Joshua DL, Shengmin S, Jungil H, et al. Peraeetylation as a means of enhancing in vitro bioactivity and bioavailability of ep~gallocate- chin-3-Gallate[ J]. Drug Metabolism and Dispositong ,2006,34 ( 12 ) : 2111-2116.
  • 10Oldendorf WH. Lipid solubility and drug penetration of the blood- brain barrier[J] . Proc Soc Exp Biol Med, 1974, 147:813-816.

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部